Baidu
map

Cell Reports:2型糖尿病胰岛素抵抗的新分子PI3K-C2α

2015-09-18 MedSci MedSci原创

对胰岛素不敏感,也被称为胰岛素抵抗,与2型糖尿病相关,并影响身体的几种细胞类型和器官。现在,来自瑞典Karolinska研究所的科学家们发现了一种机制,可以解释产生胰岛素的细胞如何能在同一时间进行胰岛素抵抗和胰岛素敏感。这项发现被刊登在Cell Reports杂志上,并可能导致未来2型糖尿病治疗新的策略。胰岛素是在降低血糖浓度的关键。2型糖尿病患者胰岛素抵抗,这意味着它们的细胞/器官对胰岛素不敏感

对胰岛素不敏感,也被称为胰岛素抵抗,与2型糖尿病相关,并影响身体的几种细胞类型和器官。现在,来自瑞典Karolinska研究所的科学家们发现了一种机制,可以解释产生胰岛素的细胞如何能在同一时间进行胰岛素抵抗和胰岛素敏感。这项发现被刊登在Cell Reports杂志上,并可能导致未来2型糖尿病治疗新的策略。

胰岛素是在降低血糖浓度的关键。2型糖尿病患者胰岛素抵抗,这意味着它们的细胞/器官对胰岛素不敏感。在2型糖尿病患者中,他们的身体试图通过生产更多的胰岛素来弥补,同时也增加了胰岛素生成细胞的数量。

寻找新的治疗策略是唯一可能获得在糖尿病患者体内发生的情况更深入的了解。一科学挑战试图解释在同一时间内一个细胞/器官在一种生物学功能中是如何能进行胰岛素抵抗,并且在另一个细胞/器官中对胰岛素敏感。

Barbara Leibiger和Ingo Leibiger博士,都是罗琳斯卡医学院分子医学和外科学奥洛夫·伯格伦教授的研究小组的成员,都在产生胰岛素的β细胞方面特别感兴趣。

“β细胞必须有胰岛素才能正常工作,”博士,副教授,以及当前研究的主要作者Barbara Leibiger说。“在一个人患有糖尿病时,β细胞变得对胰岛素不敏感。”

研究人员在以前的研究已经表明β细胞有两种受体具有不同的生物学功能,胰岛素受体A和胰岛素受体B。在目前的研究中,他们发现,在糖尿病的条件下,尽管胰岛素受体B是胰岛素不敏感的一个信号传导途径,胰岛素可以在这些条件下激活不同的信号传导途径,导致β细胞增殖。研究人员还发现,PI3K-C2α因子,可以导致从一个信号通路中切换到另一个。

“这些结果很重要,因为它解释了β细胞如何可以从分化状态到增殖状态,”目前与Berggren教授共同监督此研究的副教授Ingo Leibiger说。“这意味着,细胞是从葡萄糖反应方面变化,而不是数目增加。”

研究人员表示,参与胰岛素信号的新路径被发现,也代表了治疗糖尿病的治疗靶点的初步确定。

原始出处:

Barbara Leibiger, Tilo Moede, Meike Paschen,et al. PI3K-C2α Knockdown Results in Rerouting of Insulin Signaling and Pancreatic Beta Cell Proliferation,Cell Reports,2015.9.16

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869216, encodeId=95901869216e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 21 16:00:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749566, encodeId=6c1f1e4956692, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue May 17 03:00:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959471, encodeId=73c319594e1b3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 14 04:00:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923237, encodeId=721d192323e7e, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Jul 23 12:00:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333187, encodeId=b3d1133318e0d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Sep 20 03:00:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869216, encodeId=95901869216e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 21 16:00:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749566, encodeId=6c1f1e4956692, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue May 17 03:00:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959471, encodeId=73c319594e1b3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 14 04:00:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923237, encodeId=721d192323e7e, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Jul 23 12:00:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333187, encodeId=b3d1133318e0d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Sep 20 03:00:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2016-05-17 baoya
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869216, encodeId=95901869216e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 21 16:00:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749566, encodeId=6c1f1e4956692, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue May 17 03:00:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959471, encodeId=73c319594e1b3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 14 04:00:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923237, encodeId=721d192323e7e, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Jul 23 12:00:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333187, encodeId=b3d1133318e0d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Sep 20 03:00:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
    2016-01-14 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869216, encodeId=95901869216e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 21 16:00:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749566, encodeId=6c1f1e4956692, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue May 17 03:00:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959471, encodeId=73c319594e1b3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 14 04:00:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923237, encodeId=721d192323e7e, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Jul 23 12:00:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333187, encodeId=b3d1133318e0d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Sep 20 03:00:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1869216, encodeId=95901869216e1, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat May 21 16:00:00 CST 2016, time=2016-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749566, encodeId=6c1f1e4956692, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue May 17 03:00:00 CST 2016, time=2016-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959471, encodeId=73c319594e1b3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jan 14 04:00:00 CST 2016, time=2016-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1923237, encodeId=721d192323e7e, content=<a href='/topic/show?id=b30358095ea' target=_blank style='color:#2F92EE;'>#新分子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58095, encryptionId=b30358095ea, topicName=新分子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Sat Jul 23 12:00:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333187, encodeId=b3d1133318e0d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Sun Sep 20 03:00:00 CST 2015, time=2015-09-20, status=1, ipAttribution=)]

相关资讯

PLoS One:MicroRNA标志物或是亚洲印度表型2型糖尿病患者的特点

研究人员发现某些2型糖尿病患者“亚洲印度表型”的循环小分子核糖核酸(rna)生物标志物的作用特点——一种代谢性疾病被认为是印度韦达养生学疗法中的甜尿病。这项研究已经发表在PLoS One杂志上。 世界范围内多种组学技术正在调查并识别用于预防、诊断以及糖尿病方面治疗的生物标志物。近来,小分子核糖核酸被认为对非侵入性生物标记物有巨大潜力,用来预防、诊断和疾病预后,监测治疗和病人分层。这是因为循环小

JAMA:2型糖尿病患者使用利拉鲁肽减肥的疗效

体重减轻5%至10%可以改善2型糖尿病及相关并发症。极少有安全的,有效的体重管理的药物可供使用。该研究的目的是探讨利拉鲁肽与安慰剂对于超重或肥胖的成人和2型糖尿病患者体重管理的疗效性和安全性。研究人员进行了五十六周的随机(2:1:1),双盲,安慰剂对照,平行组试验以及12周的无药物随访观察时期。这项研究在2011年6月和2013年1月之间在9个国家的126个地点进行的。1361例患者符合评估要求,

NEJM:2型糖尿病患者接受empagliflozin治疗的心血管结果以及死亡率分析

empagliflozin,一种钠-葡萄糖协同转运蛋白2的抑制剂,除了标准护理,它对2型糖尿病高心血管风险患者的心血管发病率和死亡率目前还不清楚。研究人员随机分配患者接受10毫克或25毫克的empagliflozin或安慰剂,每天一次。主要复合终点为心血管原因,非致死性心肌梗死,或非致死性卒中死亡,作为汇集empagliflozin组与安慰剂组进行分析。关键的次要复合终点的主要成果加上因不稳定心绞

JCEM:抗生素的使用可导致患2型糖尿病的风险增加

2型糖尿病,占糖尿病患者的90%以上;流行病学研究表明,肥胖、高热量饮食、体力活动不足及增龄是2型糖尿病最主要的环境因素,高血压、血脂异常等因素也会增加患病风险。近日,一项以人群为基础的,病例对照研究显示,抗生素的使用与患2型糖尿病风险的增加相关。该研究由丹麦哥本哈根大学的克里斯蒂安发表于2015年8月的《临床内分泌学与代谢杂志》上。 数据显示,先前使用过抗生素的患者,日后发展为2型糖尿

Diabetes Care:新型二甲双胍制剂可用于治疗肾功能不全的2型糖尿病患者

近日发表于 Diabetes Care一项新的研究表明,常用于治疗2型糖尿病的二甲双胍,其发挥降糖作用的部位是在肠道而非血液中,这意味着研究人员所测试的二甲双胍延释制剂可适用于40%不能服用现有二甲双胍制剂的2型糖尿病患者。二甲双胍用于2型糖尿病的治疗已近60年,尽管其用药历史悠久,但科学家们尚未准确确定二甲双胍在人体内发挥最大降糖作用的机制及部位。而来自北卡罗莱纳大学医学院的研究明确显示,正如许

JCEM:抗生素的高使用率增加了患2型糖尿病的风险

根据发表在Endocrine Society's Journal of Clinical Endocrinology & Metabolism的一项新的研究,在几年中服用较多抗生素的患者比不服用抗生素的患者更容易被诊断出患2型糖尿病。一个人患糖尿病,其特点是高血糖,即当个体不能产生足够的激素胰岛素或胰岛素不能正常从血液中清除血糖。根据内分泌协会的事实和数据报告,超过29万美国人患有糖尿病。

Baidu
map
Baidu
map
Baidu
map